Japan is at its critical juncture. As one of the world’s most advanced super-aging societies, it faces increasingly diverse and complex healthcare needs, while also addressing important challenges related to ensuring a resilient supply of medicines, strengthening economic security, and responding to evolving public health demands.

In this environment, the importance of building a sustainable and robust healthcare system, while ensuring timely access to innovative medicines has never been greater.

EFPIA Japan’s mission is to contribute to the health and quality of life of patients in Japan through the early introduction of innovative medicines and vaccines. Today, we are particularly focused on two essential goals: ensuring that patients can access the treatments they need at the right time and delivering measurable improvements in patient outcomes as a result.

Achieving these goals will require not only the efforts of industry, but also close collaboration with government and a broad range of stakeholders. Through constructive and forward-looking dialogues, we must share challenges and co-create practical and effective solutions. EFPIA Japan is committed to further strengthening this public–private engagement.

As I take on the role of Chair, I do so at a time of significant change. I am fully committed to engaging sincerely with stakeholders and promoting responsible dialogue and collaboration to advance access to innovation and improve patient outcomes across society.

Since its establishment in 2002, EFPIA Japan has represented research-based European pharmaceutical companies operating in Japan. Drawing on the expertise and experience of its members, EFPIA Japan has continuously contributed to policy dialogue and made recommendations to advance the healthcare system. Our role is to ensure that the value of innovation is fully recognized and translated into better healthcare for patients.

Looking ahead, EFPIA Japan will place particular emphasis on policy discussions in the following areas:

• Securing appropriate incentives for innovative medicines and vaccines, enabling both high-quality healthcare and improved patient access in Japan
• Maintaining predictability and stability in the drug pricing system, to support sustainable pharmaceutical innovation and timely introduction of new drugs
• Ensuring responsible business practices through strict adherence to legal, ethical, and compliance standards

Through these efforts, we aim to strengthen the stable supply of medicines and vaccines and further reinforce the foundation for healthcare innovation in Japan. EFPIA Japan will continue to serve as a trusted partner for patients, working collaboratively across the public and private sectors to address key challenges. We remain committed to contributing to the sustainability and international competitiveness of Japan’s healthcare system, and above all, to improving patient outcomes.